TY - JOUR
T1 - COVID-19 infection during blinatumomab therapy
T2 - Is safety a dilemma?
AU - Barahona-Correa, Julián E.
AU - Rueda-Ortiz, Camilo
AU - López, María José
AU - Gualtero, Sandra
AU - Arevalo-Zambrano, Mónica
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
AB - Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
KW - Blinatumomab
KW - COVID-19
KW - SARS-CoV-2
KW - precursor cell lymphoblastic leukemia-lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85146318624&partnerID=8YFLogxK
U2 - 10.1177/2050313X221148548
DO - 10.1177/2050313X221148548
M3 - Artículo
AN - SCOPUS:85146318624
SN - 2050-313X
VL - 11
JO - SAGE Open Medical Case Reports
JF - SAGE Open Medical Case Reports
ER -